The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.